IDH2 and acute myeloid leukemia: Stein and colleagues119 treated 134 patients with de novo AML and IDH mutations using a combination of 3 + 7 and ivosidenib (IDH1 mutation; n = 60) or enasidenib (IDH2 mutation; n = 91).